Changeflow GovPing Healthcare CVR Management pays $4M for unnecessary vein pr...
Priority review Enforcement Added Final

CVR Management pays $4M for unnecessary vein procedures billed to federal healthcare programs

Favicon for www.jdsupra.com JD Supra Healthcare
Filed April 6th, 2026
Detected April 7th, 2026
Email

Summary

CVR Management, LLC (dba Center for Vein Restoration) and Center for Vascular Medicine, LLC, along with their CEO, agreed to pay $4 million to resolve False Claims Act allegations. The government alleged the defendants submitted claims to Medicare, Medicaid, and TRICARE for medically unnecessary vein procedures including sclerotherapy, radiofrequency ablation, and endovenous laser ablations. The settlement originated from a qui tam whistleblower lawsuit filed by two former employees.

What changed

CVR Management and related entities agreed to pay $4 million ($3.4 million to the federal government and $604,000 to participating states and DC) to resolve allegations they violated the False Claims Act by billing federal healthcare programs for vein treatments that did not meet medical necessity requirements. The procedures included sclerotherapy, radiofrequency ablation, and endovenous laser ablations performed for chronic venous insufficiency that allegedly lacked qualifying clinical criteria. The settlement originated from a qui tam lawsuit filed by two former employees under the FCA's whistleblower provisions; those relators will receive approximately $752,000. The settlement resolves the allegations without any determination of liability.

Healthcare providers participating in federal healthcare programs (Medicare, Medicaid, TRICARE) should review their vein treatment protocols and documentation practices to ensure procedures meet applicable medical necessity standards. Providers must ensure claims include evidence of qualifying symptoms and documentation that alternative treatments were attempted and unsuccessful before performing these procedures. The False Claims Act imposes significant liability on entities that knowingly submit claims lacking medical necessity, and qui tam whistleblower provisions create incentives for employees to report suspected fraud.

What to do next

  1. Review vein treatment billing practices to ensure medical necessity documentation meets federal healthcare program requirements
  2. Verify that claims for sclerotherapy, radiofrequency ablation, and endovenous laser ablations include qualifying symptoms and evidence of failed alternative treatments
  3. Strengthen internal compliance controls for federal healthcare program claims submission

Penalties

$4 million settlement ($3.4 million federal, $604,000 state/DC Medicaid claims); qui tam relators receive approximately $752,000

Source document (simplified)

April 6, 2026

Healthcare Management Company to Pay $4 Million to Resolve False Claims Act Allegations

LinkedIn Facebook X Send Embed

CVR Management, LLC, doing business as the Center for Vein Restoration, along with Center for Vascular Medicine, LLC and their CEO, have agreed to pay $4 million to resolve allegations that they violated the False Claims Act by submitting claims for medically unnecessary procedures used to treat chronic venous insufficiency. The government alleged that the defendants billed federal healthcare programs for vein treatments that did not meet applicable medical necessity requirements, resulting in improper payments from Medicare, Medicaid, and TRICARE.

According to the government, the defendants submitted claims for reimbursement for procedures including sclerotherapy, radiofrequency ablation, and endovenous laser ablations that were not medically necessary. Federal healthcare programs generally do not cover vein treatment procedures when performed for cosmetic purposes only and require that they be supported by specific clinical criteria, including the presence of qualifying symptoms and after a period of alternative treatment that was proven unsuccessful. The government contended that the defendants knowingly billed for services that did not satisfy these requirements.

The allegations were brought under the False Claims Act, which imposes liability on individuals and entities that knowingly submit false or fraudulent claims for payment to the government. The settlement amount totals $4 million, with approximately $3.4 million allocated to the federal government and approximately $604,000 designated for participating states and the District of Columbia to resolve Medicaid-related claims. The matter originated from a qui tam lawsuit filed by two former employees under the whistleblower provisions of the False Claims Act, which allow private individuals to bring claims on behalf of the government and share in any recovery. As part of the resolution, the relators will receive approximately $752,000. The settlement resolves the allegations without a determination of liability.

The link to the DOJ’s press release is available here.

Send Print Report

Related Posts

Latest Posts

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
King & Spalding
2026

Written by:

King & Spalding Contact + Follow Samuel Dennis Mkrtchian + Follow

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Department of Justice (DOJ) + Follow Enforcement Actions + Follow False Claims Act (FCA) + Follow Health Care Providers + Follow Healthcare Fraud + Follow Medicaid + Follow Medicare + Follow Settlement + Follow TRICARE + Follow Whistleblowers + Follow Civil Remedies + Follow Health + Follow more

King & Spalding on:

Named provisions

False Claims Act Qui Tam Provisions Medical Necessity Requirements for Vein Treatments

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
USAMO-MD
Filed
April 6th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Healthcare billing Federal healthcare program claims submission
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
False Claims Act Healthcare Fraud

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when JD Supra Healthcare publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.